Albert Bourla, Pfizer CEO (Hannes P Albert/picture-alliance/dpa/AP Images)
July 30, 2024 07:12 AM EDT
Pharma
Manufacturing

Pfiz­er ups 2024 guid­ance by $1B af­ter mul­ti­ple rounds of cost cuts

Kyle LaHucik

Senior Reporter

Pfiz­er beat Wall Street’s ex­pec­ta­tions on rev­enue in the sec­ond quar­ter and raised its full-year rev­enue guid­ance by $1 bil­lion, it

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

A service from the Financial Times